Goldman Sachs
TCRT icon

Goldman Sachs’s Alaunos Therapeutics TCRT Stock Holding History

Goldman Sachs’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-133
Closed -$77K – 5342
2019
Q1 		$77K Buy
+133
New +$55.6K ﹤0.01% 4960
2018
Q4 		– Sell
-27
Closed -$13K – 5653
2018
Q3 		$13K Hold
27
– – ﹤0.01% 5451
2018
Q2 		$12K Buy
+27
New +$17.1K ﹤0.01% 5533
2016
Q3 		– Sell
-87
Closed -$71K – 7185
2016
Q2 		$71K Hold
87
– – ﹤0.01% 6285
2016
Q1 		$96K Sell
87
-900
-91% -$921K ﹤0.01% 6093
2015
Q4 		$1.23M Sell
987
-160
-14% -$265K ﹤0.01% 4090
2015
Q3 		$1.55M Sell
1,147
-1,416
-55% -$2.34M ﹤0.01% 4045
2015
Q2 		$4.61M Buy
2,563
+1,982
+341% +$3.08M ﹤0.01% 3037
2015
Q1 		$938K Buy
+581
New +$861K ﹤0.01% 4543
2014
Q1 		– Sell
-443
Closed -$288K – 6921
2013
Q4 		$288K Sell
443
-266
-38% -$158K ﹤0.01% 5721
2013
Q3 		$419K Buy
709
+266
+60% +$120K ﹤0.01% 5292
2013
Q2 		$140K Buy
+443
New +$123K ﹤0.01% 5762

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Goldman Sachs's TCRT Position: Q1 2024 in Review

Goldman Sachs sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 68 shares — an estimated $718 sold.

Goldman Sachs first reported a position in TCRT in Q2 2013 and held it in 43 quarters. The position peaked at $6.21M in Q2 2020. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Goldman Sachs reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 68 Alaunos Therapeutics shares in Q1 2024, an estimated $718.
  • Goldman Sachs first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 43 quarters.
  • Goldman Sachs's Alaunos Therapeutics position peaked at $6.21M in Q2 2020.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.